חוב לטווח קצר להון: Nyxoah SA (NYXH)

Nyxoah S.A. (NYXH) produces innovative devices for combating sleep apnea. This chart of the valuation on the GURU.Markets platform shows the metric at 0.27, while growth rates are constrained by the slow adoption of new stimulation methods and a dependence on insurance. Nyxoah S.A. (NYXH) aims for the global scaling of the Genio system, targeting the US market. A narrow development profile is offset by a unique approach to therapy and expansion in Europe.

Nyxoah S.A. operates in the resilient medical implants sector, where demand is minimally dependent on economic cycles. The short-term debt-to-equity ratio measures the proportion of liabilities maturing within one year relative to shareholders' equity, assessing current solvency. It is critical for investors to distinguish temporary cash flow gaps from a systemic liquidity crisis. By analyzing the dynamics of short-term debt load, one can determine the risk of default or the company's financial stability.